Nuvalent (NUVL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.53 (-0.56%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Nuvalent (NUVL)
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Key Insights

Critical company metrics and information

  • Share Price

    $94.22

  • Market Cap

    $6.69 Billion

  • Total Outstanding Shares

    65.62 Million Shares

  • Total Employees

    127

  • Dividend

    No dividend

  • IPO Date

    July 29, 2021

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.nuvalent.com

Historical Stock Splits

If you bought 1 share of NUVL before March 10, 2017, you'd have 0.00 shares today.
Execution DateSplit Amount
March 10, 20171-for-1200000 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$893.81 Million
Net Cash Flow From Investing Activities, Continuing$-459.73 Million
Net Cash Flow From Operating Activities, Continuing$-153.27 Million
Net Cash Flow, Continuing$280.81 Million
Net Cash Flow From Financing Activities$893.81 Million
Net Cash Flow$280.81 Million
Net Cash Flow From Investing Activities$-459.73 Million
Net Cash Flow From Operating Activities$-153.27 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Revenues$10.20 Million
Net Income/Loss Available To Common Stockholders, Basic$-224.27 Million
Other Operating Expenses$56.57 Million
Income/Loss From Continuing Operations Before Tax$-223.67 Million
Operating Income/Loss$-240.51 Million
Preferred Stock Dividends And Other Adjustments$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-224.27 Million
Research and Development$183.94 Million
Diluted Average Shares$66.15 Million
Operating Expenses$240.51 Million
Basic Average Shares$66.15 Million
Net Income/Loss$-224.28 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$3.49
Basic Earnings Per Share$3.49
Nonoperating Income/Loss$16.81 Million
Income/Loss From Continuing Operations After Tax$-224.27 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Assets$1.19 Billion
Liabilities And Equity$1.19 Billion
Liabilities$67.73 Million
Current Liabilities$51.13 Million
Noncurrent Assets$9.18 Million
Wages$6.83 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$1.12 Billion
Current Assets$1.18 Billion
Equity$1.12 Billion
Noncurrent Liabilities$16.60 Million
Other Current Liabilities$28.37 Million
Accounts Payable$15.93 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.